What's the Problem?

92% of new drugs fail in clinical trials due to toxicity or lack of efficacy because traditional preclinical models fail to accurately reproduce the complex characteristics of human biology. Common in vitro models are basic, and while animal models provide systemic effects, they do not adequately reflect human physiology. Despite market growth, alternative tissue models still fail to integrate essential features into a single model: - Representing human physiology; - Generating reproducible data; - Being scalable in both production and analysis; - Demonstrating human genetic diversity.

How are they Solving it?

Invitrall addresses these challenges by establishing a biobank of reprogrammed donor cells, allowing the creation of genetically diverse and representative 3D tissue models. These models are not only reproducible and scalable, but also provide a solid foundation for research and development of new therapies. Our technology ensures that preclinical trial results are more predictive and relevant for patients. Our first skin model predicts skin irritation with 94% accuracy, outperforming existing market models and significantly advancing the reliability and efficacy of preclinical trials.

Go to their website

Next Startup

Migma

Go back to portfolio